Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of skin cancer.Adv Exp Med Biol. 2014; 810: 120-140
- A comprehensive pathway map of epidermal growth factor receptor signaling.Mol Syst Biol. 2005; 1: 2005.0010
- EGFR regulation of epidermal barrier function.Physiol Genomics. 2012; 44: 455-469
- Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma.Br J Dermatol. 2017; 176: 1279-1287
- Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Dermatol Res Pract. 2014; 2014: 734249
- The role of the Hedgehog signaling pathway in cancer: a comprehensive review.Bosn J Basic Med Sci. 2018; 18: 8-20
- Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy.Res Rep Biol. 2015; 6: 55-71
- Safety and tolerability of sonic hedgehog pathway inhibitors in cancer.Drug Saf. 2019; 42: 263-279
- PD-1 signaling in primary T cells.Immunol Rev. 2009; 229: 114-125
- Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.Onco Targets Ther. 2017; 10: 1803-1807
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.Hematol Oncol. 2019; 12: 92
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med. 2012; 366: 2455-2465
- Safety and tolerability of immune checkpoint inhibitors (Pd-1 and pd-l1) in cancer.Drug Saf. 2019; 42: 281-294
- Basal-cell carcinoma incidence and associated risk factors in U.S. women and men.Am J Epidemiol. 2013; 178: 890-897
- Metastatic basal cell carcinoma: report of twelve cases with a review of the literature.J Am Acad Dermatol. 1991; 24: 715-719
- Pulmonary metastasis of Basal cell carcinoma.Ann Dermatol. 2011; 23: 213-216
- Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature.Eur J Cancer. 1990; 26: 73-77
- Platinum-Based Cytotoxic Therapy in Basal Cell Carcinoma a review of the literature.Acta Oncol. 1996; 35: 677-682
- Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.ANZ J Surg. 2004; 74: 704-705
- Toxicity patterns of cytotoxic drugs.Invest New Drugs. 2003; 21: 141-148
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.BMC cancer. 2017; 17: 332
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.Eur J Cancer. 2017; 86: 334-348
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (Mikie): a randomised, regimen-controlled, double-blind, phase 2 trial.Lancet Oncol. 2017; 18: 404-412
- Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.J Am Acad Dermatol. 2021; 84: 1162-1164
- Smoothened (Smo) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.Mol Oncol. 2015; 9: 389-397
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.NPJ Genom Med. 2016; 1: 16037
- Immunosuppressive environment in basal cell carcinoma: the role of regulatory t cells.Acta Derm Venereol. 2016; 96: 917-921
- Mutational landscape of basal cell carcinomas by whole-exome sequencing.J Invest Dermatol. 2014; 134: 213-220
- Immune-associated cells in basal cell carcinomas of skin.J Cutan Pathol. 1996; 23: 140-146
- Immunotherapy for nonmelanoma skin cancer: does it have a future?.Cancer. 2002; 94: 477-485
- Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management.J Am Acad Dermatol. 2002; 47 ([quiz: 18-20]): 1-17
- Use of pd-1 inhibitors in the treatment of advanced basal cell carcinoma.Dermatol Surg. 2021; 47: 1511-1512
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.Lancet Oncol. 2021; 22: 848-857
- Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.J Am Acad Dermatol. 2019; 80: 564-566
- Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.JAMA Dermatol. 2013; 149: 541-547
- Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003.Br J Dermatol. 2007; 156: 1295-1300
- Incidence of cutaneous squamous cell carcinoma in coastal and inland areas of Western Sweden.Cancer Epidemiol. 2011; 35: e69-e74
- Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (Epidemiology of skin cancer).Br J Dermatol. 2003; 149: 1200-1206
- Chemotherapy of squamous cell carcinoma of the skin.Semin Oncol. 2012; 39: 145-149
- Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.Cancer. 1990; 66: 1692-1696
- Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.Cancer. 1985; 55: 1629-1632
- Phase ii study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas.J Clin Oncol. 2020; 38: 3051-3061
- Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.Oncotarget. 2020; 11: 378-385
- Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.J Am Acad Dermatol. 2017; 77: 1110-1113.e2
- Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.Cancer. 2018; 124: 2169-2173
- Understanding resistance to EGFR inhibitors-impact on future treatment strategies.Nat Rev Clin Oncol. 2010; 7: 493-507
- Mutational landscape of aggressive cutaneous squamous cell carcinoma.Clin Cancer Res. 2014; 20: 6582-6592
- Skin cancers after organ transplantation.N Engl J Med. 2003; 348: 1681-1691
- The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis.Front Oncol. 2019; 9: 1161
- Pd-l1 expression and tumor-infiltrating lymphocytes in high-risk and metastatic cutaneous squamous cell carcinoma.Otolaryngol Head Neck Surg. 2019; 160: 93-99
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.N Engl J Med. 2018; 379: 341-351
- Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.Ann Oncol. 2021; 32: 1276-1285
- Mechanisms of resistance to pd-1 and pd-l1 blockade.Cancer J. 2018; 24: 47-53
- Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.Nat Rev Drug Discov. 2021; 20: 168-169
- Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-vec) and ipilimumab (Ipi) in previously untreated, unresected stage IIIB-IV melanoma.J Clin Oncol. 2014; 32: 9029
- A phase 1 study of pre-operative cemiplimab (Regn2810), administered intralesionally, for patients with recurrent cutaneous squamous cell carcinoma(Cscc). Clinical trial registration. 2021. NCT03889912.(Available at:) (Accessed July 15, 2021)
- An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.J Clin Oncol. 2019; 37: TPS2671
- Efficacy and safety of first-line avelumab treatment in patients with stage iv metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial.JAMA Oncol. 2018; 4: e180077
- Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.J Immunother Cancer. 2020; 8: e000674
- Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.J Immunother Cancer. 2021; 9: e002478
- 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (Mcc) (POD1UM-201).J Immunother Cancer. 2021; 9: A574-A575
- Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.Cancer Immunol Immunother. 2021; 70: 2087-2093
- Successful treatment with taxane-based chemotherapy in advanced sebaceous carcinoma: a case report and literature review.Case Rep Oncol. 2019; 12: 47-52
- Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.Ophthalmic Plast Reconstr Surg. 2018; 34: e149-e151
- Pembrolizumab in the treatment of microsatellite instability-high sebaceous carcinoma: a case report with review of the literature.JCO Precis Oncol. 2020; 4: 61-65
- Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report.Ann Transl Med. 2019; 7: 149
- Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.J Clin Oncol. 2010; 28: 1772-1779
- Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin.Acta Oncol. 2012; 51: 952-954
- Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.J Clin Oncol. 2002; 20: 364-370
- Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin.Head Neck. 2017; 39: 679-683
- Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.Ann Oncol. 2014; 25: 2047-2052
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.J Immunother Cancer. 2020; 8 (Original research): e000775
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.Lancet Oncol. 2020; 21: 294-305
- Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629).J Clin Oncol. 2020; 38: 2916-2925
Article info
Publication history
Published online: October 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
